keyword
https://read.qxmd.com/read/38701027/health-care-decision-maker-perceptions-and-trends-in-the-utilization-of-preapproval-information-for-formulary-decision-making
#21
JOURNAL ARTICLE
Tamara Brisibe, Zade Hikmat, Tasmina Hydery, Claire Gorey, Kimberly Boswell
BACKGROUND: Preapproval information exchange (PIE) has increased between biopharma companies and health care decision-makers (HCDMs) over the last several years. However, there still exists a gap in what HCDMs need and what biopharma companies are providing. OBJECTIVE: To assess trends in the utilization of preapproval information by HCDMs and identify resources that may best support organizations in evaluating product information for formulary coverage prior to US Food and Drug Administration approval...
May 2024: Journal of Managed Care & Specialty Pharmacy
https://read.qxmd.com/read/38700853/us-hospital-service-availability-and-new-340b-program-participation
#22
JOURNAL ARTICLE
Kelsey M Owsley, Romana Hasnain-Wynia, Ronica N Rooks, Gregory J Tung, Glen P Mays, Richard C Lindrooth
IMPORTANCE: The US 340B Drug Pricing Program enables eligible hospitals to receive substantial discounts on outpatient drugs to improve hospitals' financial sustainability and maintain access to care for patients who have low income and/or are uninsured. However, it is unclear whether hospitals use program savings to subsidize access as intended. OBJECTIVE: To evaluate whether the 340B program is associated with improvements in access to hospital-based services and to test whether the association varies by hospital ownership...
May 3, 2024: JAMA health forum
https://read.qxmd.com/read/38700234/evaluating-unmet-needs-in-large-volume-subcutaneous-drug-delivery-u-s-payer-perspectives-on-a-novel-large-volume-on-body-delivery-system
#23
REVIEW
Mehul Desai, James Kenney, Edmund Pezalla
Existing healthcare systems face finite resource allocation and budgetary constraints, resulting in a substantial need for innovative solutions to enhance service delivery at reduced costs. A novel, user-friendly on-body delivery system (OBDS) was developed which enables administration of large-volume subcutaneous (SC) drugs in both clinical and home-based settings (at-home HCP administration or at-home self-administration). This research sought to evaluate the potential economic impact of at-home self- or HCP- administration with the OBDS through a comprehensive review of published literature and semi-structured interviews with 17 US payers representing approximately 227 million covered lives...
May 3, 2024: Current Medical Research and Opinion
https://read.qxmd.com/read/38699081/-i-like-the-vibes-it-gives-adolescent-perspectives-on-cannabis-billboards-and-print-advertising-in-nevada
#24
JOURNAL ARTICLE
Cara S Drake, Kim Sloan, Meghan Anderson, Kristen D Clements-Nolle, Jennifer L Pearson
An influx of laws permitting recreational cannabis sales in the US has allowed for increased advertising. The purpose of this study was to describe how adolescents perceive outdoor and print cannabis advertising and to identify aspects of advertising that are appealing or eye-catching, focusing on five themes: price promotion, sex appeal, wellness, party, and text-only. We recruited adolescents ages 11-17 to participate in seven focus groups (44 participants) from 2019 to 2020. Participants viewed cannabis advertisements and responses were summarized using deductive thematic analysis...
April 2024: Journal of Drug Issues
https://read.qxmd.com/read/38696520/explaining-why-increases-in-generic-use-outpace-decreases-in-brand-name-medicine-use-in-multisource-markets-and-the-role-of-regulation
#25
JOURNAL ARTICLE
Katharina E Blankart, Sotiris Vandoros
BACKGROUND: Healthcare systems worldwide face escalating pharmaceutical expenditures despite interventions targeting pricing and generic substitution. Existing studies often overlook unwarranted volume increases in multisource markets due to differential physician perceptions of brand name and generics. OBJECTIVE: This study aims to explain the outpacing of generic medicine use over brand name use in multisource markets and assess the regulatory role, specifically examining the impact of reference pricing on volume and intensity increases...
2024: PloS One
https://read.qxmd.com/read/38694909/sotagliflozin-versus-dapagliflozin-to-improve-outcome-of-patients-with-diabetes-and-worsening-heart-failure-a-cost-per-outcome-analysis
#26
JOURNAL ARTICLE
Weichen Zhang, Meichen Yu, Guohua Cheng
BACKGROUND AND AIM: Dapagliflozin inhibits the sodium-glucose cotransporter protein 2 (SGLT-2), while sotagliflozin, belonging to a new class of dual-acting SGLT-1/SGLT-2 inhibitors, has garnered considerable attention due to its efficacy and safety. Both Dapagliflozin and sotagliflozin play a significant role in treating worsening heart failure in diabetes/nondiabetes patients with heart failure. Therefore, this article was to analyze and compare the cost per outcome of both drugs in preventing one event in patients diagnosed with diabetes-related heart failure...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38692883/-mechanism-of-action-and-clinical-trial-results-of-lecanemab-leqembi-%C3%A2-200%C3%A2-%C3%A2-mg-500%C3%A2-%C3%A2-mg-for-intravenous-infusion-a-novel-treatment-for-alzheimer-s-disease
#27
JOURNAL ARTICLE
Tetsuhiro Niidome, Yukio Ishikawa, Tomoo Ogawa, Masaki Nakagawa, Yosuke Nakamura
Lecanemab is a humanized monoclonal antibody directed against human soluble amyloid-β aggregates. It was developed for the treatment of early Alzheimer's disease (mild cognitive impairment or mild dementia stage of Alzheimer's disease). Among the amyloid-β (Aβ) involved in Alzheimer's disease, Lecanemab selectively binds to the highly neurotoxic Aβ protofibrils, and is thought to reduce Aβ protofibrils and amyloid plaques (Aβ plaques) in the brain. The efficacy and safety of Lecanemab in early Alzheimer's disease were investigated in an international Phase II placebo-controlled study (Study 201) and an international Phase III placebo-controlled study (Study 301)...
2024: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://read.qxmd.com/read/38690551/developing-nepal-s-medicines-pricing-policy-evidence-synthesis-and-stakeholders-consultation
#28
JOURNAL ARTICLE
Zaheer-Ud-Din Babar, Santosh Dulal, Narayan Prasad Dhakal, Madan Kumar Upadhyaya, Birna Trap
OBJECTIVES: The objectives of this paper are to (a) explore stakeholders' opinions regarding Nepal's existing medicines pricing practices/situation and (b) build and present a set of medicines pricing policies for Nepal. METHODS: A review of the literature and field visits to community retail pharmacies, hospital pharmacies, wholesalers, and distributor outlets in Kathmandu were conducted to assess the medicines pricing situation. Following the literature review, preliminary meetings with stakeholders and field visits were held and a draft interview guide was prepared...
2024: Journal of Pharmaceutical Policy and Practice
https://read.qxmd.com/read/38689257/access-to-quality-assured-artemisinin-based-combination-therapy-and-associated-factors-among-clients-of-selected-private-drug-outlets-in-uganda
#29
JOURNAL ARTICLE
Moses Ocan, Loyce Nakalembe, Caroline Otike, Tayebwa Mordecai, Joan Birungi, Sam Nsobya
BACKGROUND: Malaria treatment in sub-Saharan Africa is faced with challenges including unreliable supply of efficacious agents, substandard medicines coupled with high price of artemisinin-based combinations. This affects access to effective treatment increasing risk of malaria parasite resistance development and adverse drug events. This study investigated access to quality-assured artemisinin-based combination therapy (QAACT) medicines among clients of selected private drug-outlets in Uganda...
April 30, 2024: Malaria Journal
https://read.qxmd.com/read/38687313/prescription-based-cost-analysis-of-medicines-for-cardiovascular-risk-factors-at-indian-council-of-medical-research-rational-use-of-medicine-centre-hospitals-of-india
#30
JOURNAL ARTICLE
Preeta Kaur Chugh, Pooja Gupta, Himika Wasan, C D Tripathi, Sujith J Chandy, Jaya Ranjalkar, Heber Rew Bright, Dinesh Kumar Badyal, Madhulika Peter Samuel, Ratinder Jhaj, Aditya Banerjee, Rupa Joshi, Bikash Medhi, Ajay Prakash, Sandhya Kamat, Raakhi Tripathi, Yashashri Shetty, Urwashi Parmar, Harihar Dikshit, Hitesh Mishra, Sukalyan Saha Roy, Rajiv Kumar, Suparna Chatterjee, Manjari Bhattacharya, Kalyan Samanta, Niyati Trivedi, Prashant Shah, Janki Chauhan, Raveendran Ramasamy, Jayanthi Mathaiyan, Jeevitha Gauthaman, Sandeep Kaushal, Samriti Jain, Shalini Arora, Kanchan Gupta, Jerin Jose Cherian, Nabendu Sekhar Chatterjee, Nilima Arun Kshirsagar
OBJECTIVES: India has taken several initiatives to provide health care to its population while keeping the related expenditure minimum. Since cardiovascular diseases are the most prevalent chronic conditions, in the present study, we aimed to analyze the difference in prices of medicines prescribed for three cardiovascular risk factors, based on (a) listed and not listed in the National List of Essential Medicines (NLEM) and (b) generic and branded drugs. MATERIALS AND METHODS: Outpatient prescriptions for diabetes mellitus, hypertension, and dyslipidemia were retrospectively analyzed from 12 tertiary centers...
March 1, 2024: Indian Journal of Pharmacology
https://read.qxmd.com/read/38682795/auditing-the-prescription-drug-consumer-price-index-in-a-changing-marketplace
#31
JOURNAL ARTICLE
Andrew L Hicks, Ernst R Berndt, Richard G Frank
Changes in the dynamics of prescription drug markets have raised issues regarding whether the United States Bureau of Labor Statistics' (BLS') Prescription Drug Consumer Price Index (CPI-Rx) has adequately kept up with the evolving marketplace. The CPI-Rx limits its sampling frame to retail outpatient outlets and excludes prescription pharmaceuticals dispensed in non-retail settings such as hospitals, physician/clinic outpatient facilities, and nursing homes. Thus, the CPI-Rx overlooks the increasingly important specialty pharmaceuticals dispensed in non-retail settings, whose transactions are instead captured in the overall hospital and professional services component of the medical care CPI...
April 29, 2024: Health Economics
https://read.qxmd.com/read/38677362/can-generalized-cost-effectiveness-analysis-gcea-leverage-meaningful-use-of-novel-value-elements-in-pharmacoeconomics-to-inform-medicare-drug-price-negotiation
#32
JOURNAL ARTICLE
William V Padula, Peter Kolchinsky
OBJECTIVES: Decision-makers considering using cost-effectiveness analysis (CEA) to inform health-technology assessment (HTA) must contend with documented and controversial shortfalls of CEA, including its assumption of disease severity independence and static pricing. ISPOR has recently introduced novel value elements besides direct healthcare cost and effectiveness for the patient, and these should be captured in CEA . While novel value elements advance our understanding of "what" should be measured (e...
April 25, 2024: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/38676977/the-impact-of-reference-pricing-on-prescribing-patterns-costs-and-health-services-utilization-of-proton-pump-inhibitors-a-quasi-experimental-study-in-british-columbia-canada
#33
JOURNAL ARTICLE
Shania Ws Au, Michael R Law, Lucy Cheng, Kimberlyn McGrail, Mark Harrison
INTRODUCTION: The Reference Drug Program (RDP) was established to steer patients toward equally safe and cost-effective medication under British Columbia's public drug coverage. Each RDP class covers at least one reference drug, and non-reference drugs are reimbursed up to the cost of the reference drug. In 2016, the RDP updated to include proton pump inhibitors (PPIs). This study evaluated the impact on drug expenditures, prescription patterns, and health services utilization. METHODS: We identified a cohort of individuals covered by Fair Pharmacare who used PPIs, and a control group of H2 Blockers users...
April 4, 2024: Health Policy
https://read.qxmd.com/read/38676875/cost-effectiveness-analysis-of-fluocinolone-acetonide-intravitreal-fai-implant-for-chronic-noninfectious-uveitis-affecting-the-posterior-segment-of-the-eye-niu-ps-in-china
#34
JOURNAL ARTICLE
Xin Mao, Zhanjing Dai, Jing Yang, Yuhang Wu, Fan Xie, Yun Lu, Jie Yu, Feng Chang, Yuqiong Lu
INTRODUCTION: Chronic non-infectious uveitis affecting the posterior segment (NIU-PS), which can be recurrent and persistent for numerous years, mainly affects people of working age and significantly increases the risk of visual impairment. This study aimed to investigate the cost-effectiveness of fluocinolone acetonide intravitreal (FAI) implant in the treatment of patients with chronic NIU-PS from the Chinese healthcare perspective. METHODS: A Markov model with a 2-week cycle was constructed from the perspective of the Chinese healthcare system over a lifetime time horizon...
April 27, 2024: Ophthalmology and Therapy
https://read.qxmd.com/read/38675137/transcriptomics-and-genomics-guided-drug-repurposing-for-the-treatment-of-vesicular-hand-eczema
#35
JOURNAL ARTICLE
Fieke M Rosenberg, Zoha Kamali, Angelique N Voorberg, Thijs H Oude Munnink, Peter J van der Most, Harold Snieder, Ahmad Vaez, Marie L A Schuttelaar
Vesicular hand eczema (VHE), a clinical subtype of hand eczema (HE), showed limited responsiveness to alitretinoin, the only approved systemic treatment for severe chronic HE. This emphasizes the need for alternative treatment approaches. Therefore, our study aimed to identify drug repurposing opportunities for VHE using transcriptomics and genomics data. We constructed a gene network by combining 52 differentially expressed genes (DEGs) from a VHE transcriptomics study with 3 quantitative trait locus (QTL) genes associated with HE...
March 30, 2024: Pharmaceutics
https://read.qxmd.com/read/38672610/drug-cost-avoidance-resulting-from-participation-in-clinical-trials-a-10-year-retrospective-analysis-of-cancer-patients-with-solid-tumors
#36
JOURNAL ARTICLE
Maria-Josep Carreras, Berta Renedo-Miró, Carolina Valdivia, Elena Tomás-Guillén, Anna Farriols, Laura Mañós, Jana Vidal, María Alcalde, Isabel De la Paz, Inés Jiménez-Lozano, Maria-Eugenia Palacio-Lacambra, Nuria Sabaté, Enriqueta Felip, Elena Garralda, Margarita Garau, Maria-Queralt Gorgas, Josep Monterde, Josep Tabernero
The objective of this single-center retrospective study was to describe the clinical characteristics of adult patients with solid tumors enrolled in cancer clinical trials over a 10-year period (2010-2019) and to assess drug cost avoidance (DCA) associated with sponsors' contributions. The sponsors' contribution to pharmaceutical expenditure was calculated according to the actual price (for each year) of pharmaceutical specialties that the Vall d'Hebron University Hospital (HUVH) would have had to bear in the absence of sponsorship...
April 17, 2024: Cancers
https://read.qxmd.com/read/38670855/challenges-and-facilitators-in-repeated-bio-behavioural-surveys-for-blood-borne-virus-infections-in-australian-prisons
#37
JOURNAL ARTICLE
Rugi Bah, Yumi Sheehan, Xiaoying Li, Nicola Price, Tony Butler, Gregory J Dore, Jason Grebely, Andrew R Lloyd, Behzad Hajarizadeh
BACKGROUND: Prison-based blood-borne virus (BBV) surveillance is essential for evaluation of prevention and treatment programs for high-risk populations, such as people who inject drugs who are over-represented amongst those incarcerated. Regular triennial surveillance has been in place in Australian prisons for almost two decades, but has been focused to date only on new prison entrants. Recently, the Australian Hepatitis and risk survey in prisons (AusHep study) was established to provide improved surveillance via an expanded bio-behavioural survey representative of all people in prison, including those sentenced and those on remand...
April 25, 2024: International Journal on Drug Policy
https://read.qxmd.com/read/38670605/access-to-innovative-anticancer-medicines-in-china-a-national-survey-on-availability-price-and-affordability
#38
JOURNAL ARTICLE
Wei Li, Wei Lu, Hongdou Chen, Chi Zhang, Menglei Wang, Fangfang Zheng, Huan-Huan Wu, Guang-Wen Wan, Qingqing Yang, Lu Ye
OBJECTIVES: This study aimed to investigate the availability, price, and affordability of nationally negotiated innovative anticancer medicines in China. DESIGN: Retrospective observational study based on data from a nationwide medical database. DATA SOURCES/SETTING: Quarterly data about the use of innovative anticancer medicines from 2020 to 2022 were collected from the Chinese Medicine Economic Information Network. This study covered 895 public general hospitals in 30 provincial administrative regions in China...
April 25, 2024: BMJ Open
https://read.qxmd.com/read/38668039/access-to-oncology-medicines-in-canada-consensus-forum-for-recommendations-for-improvement
#39
JOURNAL ARTICLE
Sandeep R Sehdev, Nigel S B Rawson, Olexiy I Aseyev, Catriona J Buick, Marcus O Butler, Scott Edwards, Sharlene Gill, Joanna M Gotfrit, Cyrus C Hsia, Rosalyn A Juergens, Mita Manna, Joy S McCarthy, Som D Mukherjee, Stephanie L Snow, Silvana Spadafora, David J Stewart, Jason R Wentzell, Ralph P W Wong, Pawel G Zalewski
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. These steps delay access and prevent health care providers from being able to prescribe optimal therapy. Eighteen Canadian oncology clinicians from the medicine, nursing and pharmacy professions met to develop consensus recommendations for defining reasonable government performance standards around process and timeliness to improve Canadian cancer patients' access to best care...
March 29, 2024: Current Oncology
https://read.qxmd.com/read/38666031/availability-pricing-and-affordability-of-essential-medicines-for-pediatric-population-in-malawi
#40
JOURNAL ARTICLE
Francis Kachidza Chiumia, Cynthia Chithope-Mwale, Felix Abikoloni, Vanessa Matchaya, Tadala Gaviyawo, Felix Khuluza
OBJECTIVE: Lack of access to essential medicines negatively impacts on the quality of healthcare delivery and increases morbidity and mortality, especially to the vulnerable pediatric population. We assessed the availability, pricing, and affordability of pediatric formulations in Malawi. METHODOLOGY: The study was conducted in 76 health facilities (public, faith-based and private pharmacies, and clinics) from the northern and southern regions of Malawi from March to May 2023...
2024: Frontiers in Pharmacology
keyword
keyword
109177
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.